Evidence map›Paper›PMID 28464930›Full record

ArticleTrials2017

Comparative costs and activity from a sample of UK clinical trials units.

Daniel Hind, Barnaby C Reeves, Sarah Bathers, Christopher Bray, Andrea Corkhill, Christopher Hayward, Lynda Harper, Vicky Napp, John Norrie, Chris Speed and 3 more

Abstract read
In one paragraph

Article in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. COVID-19, Social Justice, and Clinical Cancer Research.Journal of the National Cancer Institute · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel HindCTRU, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. d.hind@sheffield.ac.uk.ORCID 0000-0002-6409-4793
Barnaby C ReevesClinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Queens Building, Level 7, Bristol Royal Infirmary, Bristol, BS2 8HW, UK.
Sarah BathersCaudwell Children, Minton Hollins, Shelton Old Road, Stoke on Trent, Staffordshire, ST4 7RY, UK.
Christopher BrayDiabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK.
Andrea CorkhillUniversity of Southampton, Clinical Trials Unit, MP131, Southampton General Hospital, Tremona Road, Southampton, Hants, SO16 6YD, UK.
Christopher HaywardPeninsula Clinical Trials Unit, Peninsula College of Medicine & Dentistry, Room N14, ITTC Building 1, Tamar Science Park, Plymouth, Devon, PL6 8BX, UK.
Lynda HarperMRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6NH, UK.
Vicky NappClinical Trials Research Unit, University of Leeds, Leeds, LS2 9JT, UK.
John NorrieCentre for Healthcare Randomised Trials (CHaRT) Health Services Research Unit, University of Aberdeen, 3rd Floor, Health Sciences Building Foresterhill, Aberdeen, AB25 2ZD, UK.
Chris SpeedNewcastle Clinical Trials Unit, Newcastle University, 1-4 Claremont Terrace, Newcastle upon Tyne, NE2 4AE, UK.
Liz TremainNational Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, University of Southampton, Alpha House, Enterprise Road, Southampton, SO16 7NS, UK.
Nicola KeatCancer Research UK, Angel Building, 407 St. John Street, London, EC1V 4AD, UK.
Mike BradburnCTRU, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.

Funding

Cancer Research UK 15956
6 · The paper itself

Abstract

backgroundThe costs of medical research are a concern. Clinical Trials Units (CTUs) need to better understand variations in the costs of their activities.

methodsRepresentatives of ten CTUs and two grant-awarding bodies pooled their experiences in discussions over 1.5 years. Five of the CTUs provided estimates of, and written justification for, costs associated with CTU activities required to implement an identical protocol. The protocol described a 5.5-year, nonpharmacological randomized controlled trial (RCT) conducted at 20 centres. Direct and indirect costs, the number of full time equivalents (FTEs) and the FTEs attracting overheads were compared and qualitative methods (unstructured interviews and thematic analysis) were used to interpret the results. Four members of the group (funding-body representatives or award panel members) reviewed the justification statements for transparency and information content. Separately, 163 activities common to trials were assigned to roles used by nine CTUs; the consistency of role delineation was assessed by Cohen's κ.

resultsMedian full economic cost of CTU activities was £769,637 (range: £661,112 to £1,383,323). Indirect costs varied considerably, accounting for between 15% and 59% (median 35%) of the full economic cost of the grant. Excluding one CTU, which used external statisticians, the total number of FTEs ranged from 2.0 to 3.0; total FTEs attracting overheads ranged from 0.3 to 2.0. Variation in directly incurred staff costs depended on whether CTUs: supported particular roles from core funding rather than grants; opted not to cost certain activities into the grant; assigned clerical or data management tasks to research or administrative staff; employed extensive on-site monitoring strategies (also the main source of variation in non-staff costs). Funders preferred written justifications of costs that described both FTEs and indicative tasks for funded roles, with itemised non-staff costs. Consistency in role delineation was fair (κ = 0.21-0.40) for statisticians/data managers and poor for other roles (κ < 0.20).

conclusionsSome variation in costs is due to factors outside the control of CTUs such as access to core funding and levels of indirect costs levied by host institutions. Research is needed on strategies to control costs appropriately, especially the implementation of risk-based monitoring strategies.

Indexed as

Research DesignBudgetsCost-Benefit AnalysisCost ControlHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicResearch Support as TopicUnited Kingdom

Identifiers

PMID28464930
PMCPMC5414193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.